Variable | Overall survival | Progression-free survival | ||||
---|---|---|---|---|---|---|
HR | 95 %CL | P | HR | 95 %CL | P | |
Model 1 | ||||||
Age1,2 | / | / | NS | / | / | NS |
Symptom at presentation1,2 | / | / | NS | / | / | NS |
Histologic subtype1,2 | ||||||
CCRCC | Ref | Ref | ||||
Non-CCRCC | / | / | NS | 2.835 | 1.403–5.728 | 0.004 |
Nuclear grade1,2 | ||||||
I–II | Ref | Ref | ||||
III–IV | / | / | NS | 2.069 | 1.059–4.039 | 0.033 |
Lymph node metastasis1,2 | 4.811 | 1.365–16.961 | 0.015 | 5.739 | 2.136–15.420 | 0.001 |
Necrosis2 | / | / | / | / | / | NS |
Blood parameters | ||||||
PLR2 | / | / | / | / | / | NS |
Thrombocytosis1,2 | / | / | NS | 2.324 | 1.215–4.446 | 0.011 |
Anaemia1,2 | 2.873 | 1.310–6.299 | 0.008 | / | / | NS |
Model 2 | ||||||
SSIGN score | ||||||
Low-risk (score 2–4) | Ref | Ref | ||||
Intermediate-risk (score 5–7) | 1.447 | 0.499–4.193 | 0.496 | 1.833 | 0.871–3.858 | 0.111 |
High-risk (score 8–11) | 5.847 | 1.838–18.603 | 0.003 | 3.025 | 1.230–7.436 | 0.016 |
Blood parameters | ||||||
PLR2 | / | / | / | / | / | NS |
Thrombocytosis1,2 | / | / | NS | 2.375 | 1.245–4.469 | 0.008 |
Anaemia1,2 | 3.453 | 1.495–7.978 | 0.004 | / | / | NS |